Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the important mechanisms for
suppressing tumors of Trastuzumab. Pre-clinical data suggest that the ADCC effect of
Inetetamab, an anti-HER2 monoclonal antibody with a modified Fc segment, is 1.11 times that
of trastuzumab. Previous studies indicated that enhanced ADCC effects can be transformed into
clinical benefits. Immune induction through cyclophosphamide metronomic chemotherapy may
further enhance the ADCC effect of anti-HER2 monoclonal antibodies. Therefore, we conducted
this study to explore the efficacy and the safety of Inetetamab combined with
cyclophosphamide metronomic chemotherapy and aromatase inhibitors(AI) in the treatment of
metastatic HER2-positive and HR-positive breast cancer patients and to explore the possible
mechanisms.